Clarivate

OCTOBER 25, 2023

Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., exclusions exist for orphan drug designation and biosimilar competition ). Nonetheless, Clarivate expects the initial list to include oncology treatments KEYTRUDA® and OPDIVO®.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52

Marketing Safety Patients Competition 52

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

Clarivate

OCTOBER 7, 2021

What’s new from ESMO: Interim efficacy and safety analysis from the randomized KEYNOTE-716 study showed that the trial met its primary endpoint of RFS, with patients receiving Keytruda presenting an RFS of 90.5% Kisqali plus letrozole demonstrated a significant OS benefit, but is that enough to displace physician favorite Ibrance?

Patients 91

Patients Safety Marketing Physicians 91

Clarivate

DECEMBER 1, 2021

Treatment cost and compliance are key factors in sustaining effective long-term disease management, a powerful new oral option could be more widely accepted than the injectable competition and rapidly gain traction in the market, especially among primary care physicians. Contributors. Circulation 2021; 144(suppl1): LBS.05.

Safety 52

Safety Patients Management Marketing 52